<SEC-DOCUMENT>0001683168-22-005064.txt : 20220721
<SEC-HEADER>0001683168-22-005064.hdr.sgml : 20220721
<ACCEPTANCE-DATETIME>20220721145558
ACCESSION NUMBER:		0001683168-22-005064
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20220721
DATE AS OF CHANGE:		20220721

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PharmaCyte Biotech, Inc.
		CENTRAL INDEX KEY:			0001157075
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				621772151
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0430

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40699
		FILM NUMBER:		221096842

	BUSINESS ADDRESS:	
		STREET 1:		23046 AVENIDA DE LA CARLOTA, SUITE 600
		CITY:			LAGUNA HILLS
		STATE:			CA
		ZIP:			92653
		BUSINESS PHONE:		(917) 595.2850

	MAIL ADDRESS:	
		STREET 1:		23046 AVENIDA DE LA CARLOTA, SUITE 600
		CITY:			LAGUNA HILLS
		STATE:			CA
		ZIP:			92653

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVILEX, INC.
		DATE OF NAME CHANGE:	20090324

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EFOODSAFETY COM INC
		DATE OF NAME CHANGE:	20010808
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>pharmacyte_8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>

</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Form 8-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Current Report</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event
reported): <FONT STYLE="text-decoration: underline">July
21, 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B><FONT STYLE="text-decoration: underline">PHARMACYTE
BIOTECH, INC.</FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><FONT STYLE="text-decoration: underline">Nevada</FONT></B></FONT></TD>
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><FONT STYLE="text-decoration: underline">001-40699</FONT></B></FONT></TD>
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><FONT STYLE="text-decoration: underline">62-1772151</FONT></B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(State or other jurisdiction of incorporation)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Commission File Number)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(I.R.S. Employer Identification No.)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 50%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>3960
    Howard Hughes Parkway, Suite
    500<BR> Las Vegas, Nevada</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 50%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>89169</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Address of Principal Executive Offices)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Zip Code)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&#160;</TD>
    <TD STYLE="text-align: center">&#160;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant's telephone number, including area code:
<B>(917) 595-2850</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-decoration: underline">N/A</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed since
last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &#9744; Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &#9746; Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9744; Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9744; Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section 12(b)
of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Title of each class</FONT></TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Trading Symbol(s)</FONT></TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 34%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name of exchange on which registered</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common Stock, Par Value $0.0001 Per Share</FONT></TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">PMCB</FONT></TD>
    <TD>&#160;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The Nasdaq
Stock Market LLC</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this Chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&#160;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&#160;<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 73px"><B>Item 8.01</B></TD>
  <TD STYLE="padding-left: 10pt; text-indent: -10pt"><B> Other Events.</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 21, 2022, PharmaCyte Biotech, Inc. (&ldquo;PharmaCyte&rdquo;
or the &ldquo;Company&rdquo;) issued a press release providing an update with respect to the commencement of the pilot phase of its two-phase
pig study. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Important Additional Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company, its directors and certain of its
executive officers are participants in the solicitation of proxies from the Company&rsquo;s shareholders in connection with the Company&rsquo;s
2022 Annual Meeting of Stockholders. The Company intends to file a definitive proxy statement and a WHITE proxy card with the Securities
and Exchange Commission (&ldquo;SEC&rdquo;) in connection with any such solicitation of proxies from the Company&rsquo;s stockholders.
STOCKHOLDERS OF THE COMPANY ARE STRONGLY ENCOURAGED TO READ SUCH PROXY STATEMENT, ACCOMPANYING WHITE PROXY CARD AND ALL OTHER DOCUMENTS
FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE AS THEY WILL CONTAIN IMPORTANT INFORMATION. The Company&rsquo;s
definitive proxy statement for the 2022 Annual Meeting of Stockholders will contain information regarding the direct and indirect interests,
by security holdings or otherwise, of the Company&rsquo;s directors and executive officers in the Company&rsquo;s securities. Information
regarding subsequent changes to their holdings of the Company&rsquo;s securities can be found in the SEC filings on Forms 3, 4, and 5,
which are available on the Company&rsquo;s website at https://ir.pharmacyte.com/all-sec-filings or through the SEC&rsquo;s website at
www.sec.gov. Information can also be found in the Company&rsquo;s Annual Report on&nbsp;Form 10-K&nbsp;for the year ended April 30, 2022
to be filed with the SEC and in subsequent filings with the SEC. Updated information regarding the identity of potential participants,
and their direct or indirect interests, by security holdings or otherwise, will be set forth in the definitive proxy statement and other
materials to be filed with the SEC in connection with the 2022 Annual Meeting of Stockholders. Stockholders will be able to obtain the
definitive proxy statement, any amendments or supplements to the proxy statement and other documents filed by the Company with the SEC
at no charge at the SEC&rsquo;s website at www.sec.gov. Copies will also be available at no charge at the Company&rsquo;s website at https://ir.pharmacyte.com/all-sec-filings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 73px; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Item 9.01</B></FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Financial Statements and Exhibits. </B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Exhibits.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 73px; font-size: 10pt"><FONT STYLE="font-size: 10pt"><FONT STYLE="text-decoration: underline">Number</FONT></FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><FONT STYLE="text-decoration: underline">Description</FONT></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font-size: 10pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A HREF="pharmacyte_ex9901.htm">Press Release, dated July 21, 2022, of PharmaCyte Biotech, Inc.</A></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">104</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL document).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&#160;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date: July 21, 2022</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>PHARMACYTE BIOTECH, INC.</B></FONT></TD></TR>
  <TR>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD></TR>
  <TR>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%">&#160;</TD>
    <TD STYLE="white-space: nowrap; width: 1%"><FONT STYLE="font-size: 10pt">By:&#160;&#160;&#160;</FONT></TD>
    <TD STYLE="width: 48%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: underline">/s/ Kenneth L. Waggoner</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Kenneth L. Waggoner</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Executive Officer,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">President and General Counsel</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&#160;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>



</BODY>
</HTML>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>pharmacyte_ex9901.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="image_001.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">PharmaCyte Biotech Commences First Phase of Two-Phase
Pig Study</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">LAS VEGAS, NV, July 21, 2022--(BUSINESS WIRE)-- PharmaCyte
Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant
ascites using its signature live-cell encapsulation technology, Cell-in-a-Box<FONT STYLE="font-size: 10pt">&reg;</FONT>, announced
today that it has commenced the pilot phase of its two-phase pig study. The pig study is the last of several requirements PharmaCyte
has complied with related to the requests from the U.S. Food and Drug Administration (FDA) to lift the clinical hold on
PharmaCyte&rsquo;s planned Phase 2b clinical trial for locally advanced, inoperable pancreatic cancer (LAPC).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.3pt 0pt 5pt">PharmaCyte&rsquo;s Chief Executive Officer, Kenneth L.
Waggoner, explained, &ldquo;As part of the Investigational New Drug Application process in preparation for our planned clinical trial
in LAPC, the FDA requested data in a large animal, such as a pig, which allows for assessment of safety and distribution of CypCaps&trade;
following infusion using the clinical route of application, devices, and procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.3pt 0pt 5pt">&ldquo;The study will be conducted in two phases. The first
phase, which began today, is a short pilot study in two pigs. The objective of this pilot study is to assess microcatheter-based delivery
of CypCaps in the pancreatic arterial system. Volume of dose, number of CypCaps, and treatment location will be evaluated using imaging
and histology. Also, the CypCaps used in the study will contain radiopaque microspheres, which will be evaluated to track the movement
of the CypCaps.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.7pt 0pt 5pt">&ldquo;The data obtained from the pilot study will allow
us to finalize the full-scale pig study protocol, which will involve 90 pigs. We will then present the protocol to the FDA in our planned
Type A meeting which will provide us an opportunity to interact with the FDA to receive guidance on this and several other outstanding
issues relating to the clinical hold. Subject to any FDA-suggested modifications to the protocol, we are fully prepared to carry on with
the full-scale study. We feel that this strategy will provide the greatest likelihood for ultimate success.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.7pt 0pt 5pt">The pilot study will involve two 90-pound Yorkshire pigs.
They will receive a single intra- arterial injection of 100 CypCaps into the pancreatic arterial system through a microcatheter. Fluoroscopy
will be used to qualitatively evaluate parameters such as vascular anatomy, treatment site suitability, and acute deployment characteristics.
Over the course of a week, the animals will be clinically observed, given health and incision site checks, and body weight and condition
will be scored.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.3pt 0pt 5pt">At the conclusion of the clinical phase, whole blood and
serum will be analyzed, and tissue will be collected including the pancreas and adjacent areas and CT imaged to evaluate potential spillover
of the CypCaps containing radiopaque microspheres. After CT imaging is performed, various tissue sections will be histologically evaluated
by a board-certified veterinary pathologist. Light microscopy will be used to examine collected tissues to evaluate for any adverse effects
associated with implantation of the CypCaps. Evaluation of pancreatic samples will include the presence of microspheres, necrosis, fibroplasia,
fibrosis, inflammation, mineralization/ossification, and evidence of vascular injury. Light microscopy of additional tissues will be
reviewed to assess for adverse effects associated with treatment, including thrombosis, necrosis, inflammation, and presence of embolic
material.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">Both phases of the pig study are being conducted by CBSET,
Inc., located in Lexington, Massachusetts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">To learn more about PharmaCyte&rsquo;s pancreatic cancer treatment
and how it works inside the body to treat locally advanced inoperable pancreatic cancer, we encourage you to watch PharmaCyte&rsquo;s
documentary video complete with medical animations at: https://www.PharmaCyte.com/Cancer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">About PharmaCyte Biotech</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.7pt 0pt 5pt">PharmaCyte Biotech, Inc. is a biotechnology company developing
cellular therapies for cancer, diabetes, and malignant ascites based upon a proprietary cellulose-based live-cell encapsulation technology
known as &ldquo;Cell-in-a-Box<FONT STYLE="font-size: 10pt">&reg;</FONT>.&rdquo; This technology is being used as a platform upon which
therapies for several types of cancer, diabetes and malignant ascites are being developed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.65pt 0pt 5pt">PharmaCyte&rsquo;s therapy for cancer involves encapsulating
genetically engineered human cells that convert an inactive chemotherapy drug into its active or &ldquo;cancer-killing&rdquo; form. For
pancreatic cancer, these encapsulated cells are implanted in the blood supply to the patient&rsquo;s tumor as close as possible to the
site of the tumor. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at
one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When
the ifosfamide flows through pores in the capsules, the live cells inside act as a &ldquo;bio-artificial liver&rdquo; and activate the
chemotherapy drug at the site of the cancer. This &ldquo;targeted chemotherapy&rdquo; has proven effective and safe to use in past clinical
trials and we believe results in little to no treatment related side effects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.3pt 0pt 5pt">PharmaCyte&rsquo;s candidate therapy for Type 1 diabetes
and insulin-dependent Type 2 diabetes involves encapsulating a human cell line that has been genetically engineered to produce and release
insulin in response to the levels of blood sugar in the human body. The encapsulation of the cell line will be done using the Cell-in-a-Box<FONT STYLE="font-size: 10pt">&reg;</FONT>
technology. Once the encapsulated cells are implanted in a diabetic patient, we anticipate that they will function as a &ldquo;bio-artificial
pancreas&rdquo; for purposes of insulin production.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05pt 0pt 5pt">PharmaCyte&rsquo;s therapy for malignant ascites involves
using the same encapsulated cells PharmaCyte employs for pancreatic cancer but placing the encapsulated cells in the peritoneal cavity
of a patient and administering ifosfamide intravenously.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">Safe Harbor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">This press release may contain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995 that express the current beliefs and expectations of PharmaCyte&rsquo;s
management and Board of Directors. Any statements contained in this press release which do not describe historical facts are forward-looking
statements subject to risks and uncertainties that could cause actual results, performance and achievements to differ materially from
those discussed in such forward-looking statements. Factors that could affect our actual results include our ability to satisfactorily
address the issues raised by the FDA in order to have the clinical hold on our IND removed, as well as such other factors that are included
in the periodic reports on Form 10-K and Form 10-Q that we file with the U.S. Securities and Exchange Commission. These forward-looking
statements are made only as of the date hereof, and we undertake no obligation to update or revise the forward-looking statements, except
as otherwise required by law, whether as a result of new information, future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.3pt 0pt 5pt">More information about PharmaCyte Biotech can be found
at https://www.PharmaCyte.com. Information may also be obtained by contacting PharmaCyte's Investor
Relations Department.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">View source version on businesswire.com:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">https://www.businesswire.com/news/home/20220721005301/en/</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">Investor Relations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 304.15pt 0pt 5pt">PharmaCyte Biotech, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 304.15pt 0pt 5pt">Telephone: 917.595.2856</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 243.95pt 0pt 5pt">Email: InvestorRelations@PharmaCyte.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 243.95pt 0pt 5pt">Attn: Dr. Gerald W. Crabtree</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">Source: PharmaCyte Biotech, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1"  [ .$# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#V6BFR)YL;
M)N9<C&5."/QKS"VO]7N_B==>'SK=]'9)N92A7>,*"!DCWJHQN3*7*>HYI:\S
MU+7]>\$>++*TO[XZGI5ZP"M*@$B9.#R.XR/J*ZCQ)XVL_"LL*:E:7FV8D121
M*K!B,9_BSW%'(]!*:UOT.DHJ&WG:>W61X7B9AG8^,C\B17.S^.[2W\1)H<EA
M??VA(1M0*F#D9SG=Z4DFRFTMSJ**0'*@D8R.A[5D3>)K*'Q3!H+D_:IH3,#V
M&.B_4C)_"E:X-V-BBDS7+WWCRUT_7%T>73M1:^<92..-6WC!.0=WL::3>P-I
M;G4T5S5KX[TR76$TN\AO-/O9,!([N+8'STP<D5TF:&FMP33V%HK*T/Q!:Z\E
MV;7(:TN'MY%/4%3C/T/45IE@H)/ '))I G<=167H&OVOB*QDN[+=Y23/#D]]
MIQGZ'K6GF@:=Q:2LCP]XELO$D5W)8DXMIVA;/?'1A['M6E=W<-C:2W-RXCAA
M0N['L!UH:MH)--7):*X#1]7UOQ_<SSV5T^D:)"^Q7C4&:8_4_=_#UK9G\'3F
M,_9O$NN12]G:X#C\1BJ<;:,2E?5(Z:EKB+#Q!J/A?1;R3Q*+O4/LMRT9N8(U
M("8&TD9!QSUKI=!URV\1:3%J-FKB&0D /C<,''(!.*3BT"DF:5%<_J'C"VT_
M7&TG['=SW*P_:"8E4JJ<Y))/'3O5-?'T8LOM<F@:ZD 3S"YM1M"XSG.>E'*P
MYD=917(V/Q#M=3M?M-AHVM7,&2OF16H89'4?>JZ_C"WC\-_VVUC>?95W&1=J
MAX\-CE2?6CE8<R.AHKE+/Q_;ZC9K=V6BZU<6[9VR1VP(.#@_Q5T&E:C'JVF6
M]]$DD<<Z;U6088#W%#30U)/8MT4F:*0PKRG3G\OXZ7[X9ML;G"C)/R#H*]6/
M SVKR32[N#_A>UXWFI@[T!W#&=@_PK2'4RJ=/4Z34] O?%_BNPN[RV:TTG3C
MO19<>9.^0?N_PC@=:QOC4<0Z(?2:0_HM>H @@$<BO+?C7-&J:*I==PED8C/(
M'RT0=Y(*BM%G6+XXL0JC[#K'3_H'R?X5Q+:C%JOQLTVYABGB0H%VSQ&-N$;L
M>:]8AD66%61PRD#D'->7:M<PCX[:>3(F%15)W#@E&_QIPMJ*=[+4]1N)X[6W
MEGF8+%$I=V/8 9->,Z[:7PTVV\>J'6ZDOO."G^"#I&/R'_CU=OX_U%;J&Q\.
MVLZ"XU:81R$,,I".7/X]/SJQ=?#S2I]-DM%EO@ACV(K7<C(O''RYQ@<<4H/E
MU8YIRT1T.F7\.K:9;7UN<Q7$8D7\1TKSGQ#/#:_&W2IKB5(HEA&YW8*H^5^I
M-2_"?6_L\=[X;OY52YLI6,2LW49PP'T//XU5\0O:S_&S2X[CR9(O*5'5\%<E
M7P"#]13C&TFA2ES13-#Q=:0^,_%6C6>DRQS-9-YUU<Q,&6),@@9'<D' KT"Z
MG6UM9IV^[$C.?H!FO.?%>CW7@W68_%/AN$?93A;VUC&$*_WL#M_(\ULZYXNT
M_4OAQJ6I:?<H0]NR;"P#(S<;2/7FDU=*VPT[7ON<)X*U*Z\*^);&>^;_ $'7
MHMY;L"6."?<']&KT;QO?3FQ@T73FQ?ZLY@0C_EG'CYW_  '\ZQ?$7A-=9^&>
MGQ6@#7=A;))"5.=Q"C<OX_S J7X<QWNMH/$>K_--Y*VEKGLB_>;ZL?Y53L_>
M)BFO=[E/X-3%-,U73V/-M=9Q]1@_^@UTWC?4Y;'03;69_P!.U!Q:6X'7<_!/
MX#)KCO 4\6E_$KQ)IS2*HD9B@+8R0^?Y-6K)#;^-_'EPCSN;#18PB&&4H6G;
MJ00<\ 8I27O7'%^Y9&/HL ^'WQ+72MS?V=J4*+&S'^+'!_[Z!'_ JZ/XKS2P
M^ [D1Y DEC1\?W=W_P!85B?$7P7!9>'O[5T^6[-S9.KEIKAY,)GG&X\8.#^%
M='8W-I\0O ?E22KON8?+E"D$QRCOCZ@'Z4-WM($K7@-^%ZQCP#I_EXY,A;'K
MO-=::\D\(ZY=?#N]FT+Q/$\-E)(7AN0I* ]R#_=/Z5Z2/$>C-;^>-5L?*(SO
M\]<?SJ9Q=[E4Y+E+T]O%<P2031J\4BE74CA@>"*\KTW4#\+O$M_I=]YCZ3<H
M;BT8#)W=A]3]T^^*]"T#78O$,%S=VA#6:S&*&0 _O H&6^F<X^E<!\9)8AJ&
M@ NNY9')YY RE.&_*Q5-N9'8^$M&E@M;C4]50-J>J'S;@'G8O\,8]@*N^*QC
MPEJO_7K)_P"@FM9'5QN1@P/<'-8_B^5(O".JM(P4?97Y)QVJ4[LNUHG/?![_
M )$<?]?,G]*U_'B*G@36 BA0823@=\BL3X.31MX*,8=2ZW,F5SSVK:^(,B1^
M!=6WL!F' R<9.15/XR%_#^1S'P^\46VD^"+6&:SU&3RVD8O#:LZ??)X(KT'3
M+F*\TVVN8(S%%-&'1",%01G&*XKX8:YI<'@>VMY]0M8I8GDWQR2JI&6)'!/H
M:[+2;^UU*P$]@5:V#,B,OW6"DC(]LBE/=CI[+4NT445!H(RAU*L 5(P0>]4O
M[#TO.?[-L\YSGR%S_*K]% #40(H50 H&  .!5:?2K&ZD,EQ96TKGJTD2L?S(
MJW10!#!;0VL?EV\21)_=10!^55VT736<NVGVA<G)8PJ3GZXJ]10!2.C:<7WF
MPM"X_B,*Y_/%7,<4M% %(Z/IQF\[[!:>;G=O\E=V?7.*RM2FTBSU(P2:,MQ-
MY?G.\=LK$#)&3W[5T5<MJEO>77BN6.QNDMI#8C+LF[C<>GI6U&*E+WCGQ$I0
MBN7>YT%G/;WEC'+:[6MW7Y<#C'IBH?[#TOG_ (EMESU_<+S^E5/"TZR:.(4B
M6/[+(T#!6W*Q'4@]\YK9J)QY9.)I3ESP4F4-(N+6XM7^PP""**5XM@4*,@X/
M J['&D2!(T5$7HJC 'X5C>%/^/"[_P"OR;_T*MNG5BHS:0J,G*"DSG=0NM+3
M4'A@TA+^]7YI/*@4E<_WF/>I-'N],:],"::NG7P7/EM"J,P]B.M-\)&-;2ZA
M;B\2X<S@_>))X/TQBD\1E'O])BA(-Z+D,N.JI@[B?:MN2/,Z=OG_ %T.=5)\
MBJW^7]=3=EACN(FCFC22-N&1U!!^H-95X]EX?Q+;Z2?F!+O:P*-H'J16S5/6
M/^0/>_\ 7!_Y&N>%N9)G54ORMK<JV-]!X@A99M.E$&T,#<Q#8^?3/6F?\(?X
M?\S?_8UCNZY\D59T'_D!6/\ UP7^5:%54TDU'0FE=P3EJS 37K>TDFL['2KM
MTMG,9%O"-@/MBM$Z=87P6XN-/@:2103YT*EA['(K T^TO[C4]7-EJ'V51=$%
M?*#9.T<\UU,*ND*+(_F.% 9\8W'UQ5UHQC91_4RP\YSNY;?(:J6]A;ML6."%
M!N(4!5%8,^NPZE'^[T6YO[0'B0Q JWN >M6?%Z._AV?8"5#*9 .I0,-WZ5J6
MDL,UI$]JRF$H-FT\8I148PYFKE2E*4^1.UD0:=:6(BCN;2QBMFD7/$(1A['%
M&KBS33Y;B_MH[B*!2^UT#?D#5X'(X.:S/$O_ "+=_P#]<6J(+FFEYFDVXTV^
MR()].T1=-:^DTFS,:Q>;C[.F<8SZ5HZ=]G_L^ VD2PP,@9(U4*%!YZ"N:NM/
MU1?#4DC:MNA^RY\KR5Y&WIFNAT?_ ) UG_UQ7^5:5(1C&Z=]3*E4E*=FK:>1
M=HI**YSI'4444P"BBB@ HHHH **** "LS4-!L]1NQ<7 E\P)L.R0J"N<X./K
M6G2549.+NF3*$9JTE<AM+2"RMT@MHECB3HJBIJ**EMMW8TDE9%>RL8;"-TMP
M0KR-(<G/S$Y-6:04M-MMW8))*R,O4/#]EJ%P+AQ)#< 8\V%RC$>Y'6G:;H=G
MILC2Q*[SN,--*Q=R/3)K1H%5[2=N6^A'LH<W-;46HKB%+B"2&0$I(I5@/0U+
M25!;U(K:W2UMHX(@1'&H503G@5+12T/N"5M#%G\+Z?<7,L[>>KRMN?9,R@GZ
M"M:&)8(4B3.U%"C)R<#WI_>BJE.4M&R8TXQ=XH1@&4A@"#U!K$?PEIY=C$US
M;HYRT<,S*A_"MRD-$9RC\+%.G"?Q*XRVMX[2WC@A!$<:A5!.>*;=VL=[:2V\
MX)CE7:P!QQ4PHI7=[EV5K="N]G%)8-9L#Y)C\LC/\.,=:DMX4MK>.&,82-0J
1@^@J6DHN]@LD[A1112 __]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
